GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (FRA:7EY) » Definitions » Cyclically Adjusted PB Ratio

Kiora Pharmaceuticals (FRA:7EY) Cyclically Adjusted PB Ratio : (As of Sep. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kiora Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kiora Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Kiora Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=10.352/132.5538*132.5538
=10.352

Current CPI (Jun. 2024) = 132.5538.

Kiora Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201409 -28,070.313 100.428 -37,049.768
201412 -29,656.250 99.070 -39,679.626
201503 1,671.186 99.621 2,223.646
201506 678.333 100.684 893.049
201509 5,444.366 100.392 7,188.571
201512 3,935.211 99.792 5,227.123
201603 3,887.662 100.470 5,129.116
201606 3,468.072 101.688 4,520.747
201609 1,624.157 101.861 2,113.549
201612 -165.957 101.863 -215.960
201703 -533.333 102.862 -687.282
201706 1,274.608 103.349 1,634.791
201709 178.683 104.136 227.445
201712 -508.750 104.011 -648.361
201803 1,337.500 105.290 1,683.840
201806 1,477.325 106.317 1,841.901
201809 1,183.209 106.507 1,472.573
201812 968.557 105.998 1,211.212
201903 1,052.725 107.251 1,301.091
201906 886.288 108.070 1,087.086
201909 561.329 108.329 686.852
201912 526.037 108.420 643.130
202003 656.265 108.902 798.799
202006 538.911 108.767 656.766
202009 393.852 109.815 475.405
202012 518.341 109.897 625.205
202103 540.314 111.754 640.876
202106 440.010 114.631 508.805
202109 420.713 115.734 481.855
202112 366.742 117.630 413.273
202203 290.563 121.301 317.518
202206 228.347 125.017 242.114
202209 88.631 125.227 93.817
202212 53.950 125.222 57.109
202303 44.483 127.348 46.301
202306 16.399 128.729 16.886
202309 8.887 129.860 9.071
202312 6.544 129.419 6.702
202403 11.007 131.776 11.072
202406 10.352 132.554 10.352

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kiora Pharmaceuticals  (FRA:7EY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals Business Description

Traded in Other Exchanges
Address
332 Encinitas Boulevard, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals Headlines

No Headlines